Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

abbvie s.r.o., slovensko - botulotoxín - 63 - myorelaxantia

Európska únia - slovenčina - EMA (European Medicines Agency)

biolitec pharma ltd - temoporfín - head and neck neoplasms; carcinoma, squamous cell - antineoplastické činidlá - foscan je indikovaný na paliatívnu liečbu pacientov s pokročilých hlavy a krku spinocelulárny karcinóm zlyhanie predchádzajúcich terapií a nevhodné pre rádioterapia, chirurgia alebo systémová chemoterapia.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

abbvie s.r.o., slovensko - botulotoxín - 63 - myorelaxantia

Európska únia - slovenčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medreg s.r.o., Česká republika - eplerenón - 50 - diuretica

Európska únia - slovenčina - EMA (European Medicines Agency)

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - iné alimentárny trakt a metabolizmus výrobky, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Európska únia - slovenčina - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofília a - antihemoragiká - liečba a profylaxia krvácania u pacientov s hemofíliou a (vrodená deficiencia faktora viii). advate neobsahuje von willebrand faktor v farmakologicky účinných množstvách, a preto nie je uvedené v von willebrand ochorenia.

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - neoplazmy prsníkov - endokrinné terapia, anti-estrogény - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - alebo perimenopauzálnych žien, kombinácia liečby s palbociclib by mali byť kombinované s luteinizačného hormónu uvoľňujúci hormón (lhrh) agonist.

Európska únia - slovenčina - EMA (European Medicines Agency)

vanda pharmaceuticals netherlands b.v. - tasimelteon - poruchy spánku, cirkadiánny rytmus - psycholeptika - hetlioz je indikovaný na liečbu 24-hodinovej poruchy spánku (non-24) u úplne slepých dospelých.

Európska únia - slovenčina - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresíva - pozrite si dokument s informáciami o produkte.